177Lu-DOTATATE pokazala efikasnost protiv G2 i G3 gastroenteropankreatičnih NET-ova
Iako retki i sporo rastući tip raka, neke neuroendokrine tumore (NET) ipak karakteriše brza progresija i loša prognoza. Originalna autorizacija za 177Lu-DOTATATE (Lutathera®) je zasnovana na rezultatima ispitivanja NETTER-1 za neresektabilne NET-ove srednjeg creva. U toku ispitivanja NETTER-2177Lu-DOTATATE je sada takođe pokazala svoju efikasnost kod pacijenata sa uznapredovalim gastroenteropankreatičnim NET-ovima (GEP-NET) G2 i G3, i pritom - kao početni ili prvi tretman za novodijagnostikovane pacijente.
Die Zukunft hat begonnen. Therapie auf dem nächsten Level.
The future has started. Experience therapy on the next level.
Budućnost je počela. Terapija na sljedećoj razini.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Therapie der Zukunft: we fight your cancer
